Discover
ALXO
ALX Oncology Holdings Inc.
2.06
2 x 1.50
2 x 2.54
bid
ask
-
0.01
0.48%
2 @ 04:00 PM
2.09 +0.03 (1.33%)
| Ytd | 82.30% | |
| 1y | 375.75% |
1.98
day range
2.11
0.42
52 week range
2.66
| Open | 2.04 | Prev Close | 2.07 | Low | 1.98 | High | 2.11 | Mkt Cap | 277.20M |
| Vol | 1.23M | Avg Vol | 1.42M | EPS | -1.49 | P/E | N/A | Forward P/E | -0.68 |
| Beta | 1.04 | Short Ratio | 8.58 | Inst. Own | 88.21% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-08 | 50-d Avg | 1.80 | 200-d Avg | 1.71 | 1yr Est | 7.67 |
ALXO News
globenewswire.com
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Onco
benzinga.com
ALX Oncology Appoints Scott Garland Chairman, Effective Immediately, Succeeding Corey Goodman
ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology co
globenewswire.com
ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Couns
Strengthens Leadership with Veteran Executives with Decades of Industry Experience Scott Garland Suc